Metraipolis › archive › dc_6aa64583fcd9
Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis — Europe PMC PMID:41349474
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41349474
- DOI
- 10.1093/oncolo/oyaf401
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T08:38:02.563Z
- SHA-256 of the archived text
51f6e8bc83781e9ad367c5051f9a6baa65389ca3a5100f7a64ec80913c861753- Stable URL of this page
https://metraipolis.com/documento/dc_6aa64583fcd9
How to cite
Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis — Europe PMC PMID:41349474 — Europe PMC (en), https://europepmc.org/article/MED/41349474 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6aa64583fcd9 (Metraipolis archive dc_6aa64583fcd9, sha256 51f6e8bc83781e9ad367c5051f9a6baa65389ca3a5100f7a64ec80913c861753)
BibTeX
@misc{dc6aa64583fcd9,
title = {Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis — Europe PMC PMID:41349474},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41349474},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6aa64583fcd9; sha256 51f6e8bc83781e9ad367c5051f9a6baa65389ca3a5100f7a64ec80913c861753},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41349474. Agents can read the archived copy with the MCP tool read_document.